Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats - PubMed (original) (raw)
. 2005 Sep;289(3):H1013-9.
doi: 10.1152/ajpheart.00068.2005. Epub 2005 Apr 15.
Affiliations
- PMID: 15833808
- DOI: 10.1152/ajpheart.00068.2005
Free article
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats
Michiya Igase et al. Am J Physiol Heart Circ Physiol. 2005 Sep.
Free article
Abstract
When increased in vascular tissues, angiotensin-converting enzyme 2 (ACE2), a carboxypeptidase that hydrolyzes angiotensin II to angiotensin-(1-7), may augment the growth inhibitory and vasodilatory effects of the heptapeptide. We investigated the regulation of ACE2 and angiotensin-(1-7) expression in aortas and carotid arteries of 12-wk-old male spontaneously hypertensive rats (SHR) by determining the effect of sustained angiotensin type 1 (AT(1)) receptor blockade with olmesartan (10 mg.kg(-1).day(-1), n = 13) compared with those that received atenolol (30 mg.kg(-1).day(-1), n = 13), hydralazine (10 mg.kg(-1).day(-1), n = 13), or vehicle (n = 21). Systolic blood pressures were approximately 30% lower (P < 0.05) in rats treated for 2 wk with olmesartan compared with vehicle-treated rats. Both atenolol and hydralazine produced similar decreases in systolic blood pressure. ACE2 mRNA in the thoracic aorta of olmesartan-treated rats (n = 8) was fivefold greater (P < 0.05) than that in vehicle-treated rats (n = 16), whereas atenolol (n = 8) or hydralazine (n = 8) had no effect. Immunostaining intensities in rats treated with olmesartan (n = 5) were also associated with increased (P < 0.05) ACE2 and angiotensin-(1-7) in thoracic aorta media compared with vehicle-treated rats. In contrast, immunostaining intensities for both ACE2 and angiotensin-(1-7) were not different from vehicle (n = 5) in carotid arteries of SHR medicated with either atenolol (n = 5) or hydralazine (n = 5). A comparison of vessel wall dimensions showed that olmesartan selectively reduced the thoracic aorta media-to-lumen ratio (P < 0.05) and media thickness (P < 0.05) without an effect on carotid artery morphometry. Compared with vehicle-treated SHR, vascular hypertrophy determined from media and lumen measurements was not changed in SHR given either atenolol or hydralazine. These data represent the first report of ACE2 and angiotensin-(1-7) expression in the aorta and carotid arteries of SHR. Increased ACE2 and angiotensin-(1-7) in association with altered dimensions of the thoracic aorta but not carotid arteries in response to olmesartan treatment provides evidence that this pathway is regulated by AT(1) receptors and may be important in mediating the pressure-independent vascular remodeling effects of angiotensin peptides.
Comment in
- Regulation of ACE2 and ANG-(1-7) in the aorta: new insights into the renin-angiotensin system in the control of vascular function.
Dantas AP, Sandberg K. Dantas AP, et al. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H980-1. doi: 10.1152/ajpheart.00476.2005. Am J Physiol Heart Circ Physiol. 2005. PMID: 16100255 Review. No abstract available.
Similar articles
- Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Igase M, et al. Hypertens Res. 2008 Mar;31(3):553-9. doi: 10.1291/hypres.31.553. Hypertens Res. 2008. PMID: 18497476 - Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, Ferrario CM. Yokoyama H, et al. Am J Hypertens. 2005 Jul;18(7):922-9. doi: 10.1016/j.amjhyper.2005.01.009. Am J Hypertens. 2005. PMID: 16053988 - Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Agata J, et al. Hypertens Res. 2006 Nov;29(11):865-74. doi: 10.1291/hypres.29.865. Hypertens Res. 2006. PMID: 17345786 - Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J, Koike H. Nussberger J, et al. Clin Ther. 2004;26 Suppl A:A12-20. doi: 10.1016/s0149-2918(04)90141-5. Clin Ther. 2004. PMID: 15291375 Review. - Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S, Miyazaki M. Takai S, et al. Am J Cardiovasc Drugs. 2006;6(6):363-6. doi: 10.2165/00129784-200606060-00002. Am J Cardiovasc Drugs. 2006. PMID: 17192125 Review.
Cited by
- Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.
Takai S, Jin D, Aritomi S, Niinuma K, Miyazaki M. Takai S, et al. Hypertens Res. 2013 Apr;36(4):342-8. doi: 10.1038/hr.2012.187. Epub 2012 Nov 29. Hypertens Res. 2013. PMID: 23190689 Free PMC article. - Renin-angiotensin system at the interface of COVID-19 infection.
Gul R, Kim UH, Alfadda AA. Gul R, et al. Eur J Pharmacol. 2021 Jan 5;890:173656. doi: 10.1016/j.ejphar.2020.173656. Epub 2020 Oct 18. Eur J Pharmacol. 2021. PMID: 33086029 Free PMC article. Review. - Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury.
Ventura D, Carr AL, Davis RD, Silvestry S, Bogar L, Raval N, Gries C, Hayes JE, Oliveira E, Sniffen J, Allison SL, Herrera V, Jennings DL, Page RL 2nd, McDyer JF, Ensor CR. Ventura D, et al. Open Forum Infect Dis. 2021 Apr 4;8(10):ofab170. doi: 10.1093/ofid/ofab170. eCollection 2021 Oct. Open Forum Infect Dis. 2021. PMID: 34642634 Free PMC article. Review. - Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2 (Review).
Cai L, Guo X, Cao Y, Ying P, Hong L, Zhang Y, Yi G, Fu M. Cai L, et al. Int J Mol Med. 2021 Apr;47(4):43. doi: 10.3892/ijmm.2021.4876. Epub 2021 Feb 12. Int J Mol Med. 2021. PMID: 33576441 Free PMC article. - COVID-19 in people with diabetes: understanding the reasons for worse outcomes.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. Apicella M, et al. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792. doi: 10.1016/S2213-8587(20)30238-2. Epub 2020 Jul 17. Lancet Diabetes Endocrinol. 2020. PMID: 32687793 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials